Recombinant PDCD1 (Spartalizumab Biosimilar) anticorps

N° du produit ABIN7200669

L’anticorps Souris Monoclonal anti-PDCD1 (Spartalizumab Biosimilar) a été validé pour FACS et in vivo. Il convient pour détecter PDCD1 (Spartalizumab Biosimilar) dans des échantillons de Humain.

Aperçu rapide pour Recombinant PDCD1 (Spartalizumab Biosimilar) anticorps (ABIN7200669)

Antigène: PDCD1 (Spartalizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp PDCD1 (Spartalizumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Détail du produit anti-PDCD1 (Spartalizumab Biosimilar) anticorps

Fonction: Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody

Specificité: The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.

Attributs du produit: Recombinant Humanized IgG4 Monoclonal Antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.

Isotype: IgG4 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur PDCD1 (Spartalizumab Biosimilar)

Antigène: PDCD1 (Spartalizumab Biosimilar)

Classe de substances: Biosimilar

Sujet: Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.